DFE Pharma

About DFE Pharma

DFE Pharma is a global leader in excipient products and services for usage in the pharmaceutical, biopharmaceutical and nutraceutical industries. We strive to develop, produce and supply the highest quality functional excipients for oral solid dose, inhalation and parenteral formulations.

Our products play essential roles as fillers, binders, disintegrants and stabilizing agents in formulations. They enable the active ingredients to be dosed and released into the patients' system in a predictable, accurate and effective manner. With over a century of experience, we are driven by our purpose your medicines, our solutions. Moving to a healthier world.

Learn more at dfepharma.com  

DFE Pharma

  • DE
  • 2015
    On CPhI since
  • 1
    Certificates
  • 250 - 499
    Employees
Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy
9-11 November 2021

Products from DFE Pharma

  • Pharmacel® 112

    Product Pharmacel® 112

    DFE Pharma has various microcrystalline cellulose offerings under the brand name Pharmacel®, including Pharmacel® 101, 102 and 112. Pharmacel® 112 is specifically designed for formulating active pharmaceutical ingredients with a high sensitivity for moisture.

    Pharmacel® is supplied in 25 kg bags.

  • Pharmatose® 200M

    Product Pharmatose® 200M

    DFE Pharma offers a wide range of milled and sieved products, including the Pharmatose® and LactoPress® brands. Varying degrees of particle sizes can be offered to allow pharmaceutical companies to choose the grade best fitting their formulation needs.

    Products can be supplied in various offerings, including big bags, 25 kg bags, drums and boxes.


  • SuperTab® 11SD

    Product SuperTab® 11SD

    SuperTab® 11SD is a highly consistent, spray-dried monohydrate lactose enabling efficient tableting by offering free flow properties. It is designed to combine the high compactibility of finely milled lactose with good flow properties of spherical spray-dried particles. For those formulators that require additional compaction or flow DFE Pharma offers LactoPress® 250SD or SuperTab® 14SD.

    SuperTab® 11SD is available in 25 kg bags or 40 kg drums.

  • SuperTab® 21AN

    Product SuperTab® 21AN

    SuperTab® 21AN is a highly consistent anhydrous lactose with excellent compaction and re-compaction. Its low moisture content makes SuperTab® 21AN a popular choice in formulating with moisture sensitive API’s. For those formulators that require additional compaction and/or flow DFE Pharma offers SuperTab® 22AN and/or SuperTab® 24AN.

    SuperTab® 21AN is available in 25 kg bags and 50 kg drums.

  • SuperTab® 30GR

    Product SuperTab® 30GR

    SuperTab® 30GR is a highly consistent, agglomerated monohydrate lactose developed for an optimal flow/compaction ratio in direct compression. It is a product with ideal mixing properties for low to high dose formulations, and thereby contributes to an efficient development process.

    SuperTab® 30GR is available in 25 kg bags or 40 kg drums.

  • SuperTab® 40LL

    Product SuperTab® 40LL

    SuperTab® 40LL is a co-processed excipient combining anhydrous lactose with lactitol. SuperTab® 40LL combines all required functionalities into one single excipient. It redefines the limits of direct compression, making it the excipient of choice for mini-tablet and/or other challenging formulations.

    SuperTab® 40LL is available in 35 kg drums.

  • BioHale® Sucrose

    Product BioHale® Sucrose

    BioHale® Sucrose is a non-reducing crystalline disaccharide made up of glucose and fructose. Sucrose is commonly used in the biopharmaceutical industry to stabilize proteins, lipids, and carbohydrates during the formulation process. The utility and function is driven by its unique chemical and physical properties, especially in aqueous solutions. Sucrose has the ability to form a glassy sugar coating around the protein which inhibits molecular mobility, thereby stabilizing the protein.
  • BioHale® Trehalose Dihydrate

    Product BioHale® Trehalose Dihydrate

    BioHale® Trehalose Dihydrate is a non-reducing disaccharide consisting of two glucose molecules which are linked by an α, α-1,1 bond. It is used in the pharmaceutical industry as a stabilizer of biologics.

    Trehalose Dihydrate has proven to be highly effective in protecting cell membranes against dehydration and preventing dehydration-induced fusion between liposomal membranes. The efficacy of Trehalose as a dehydroprotectant is mainly due to its beneficial glass-forming ability.

    Our product is made of highest purity and low endotoxin which can be used for various dosage forms, such as parenteral, inhalation or oral solid. It complies with all relevant pharmacopeias Ph. Eur., USP-NF, JP and ChP.

  • Lactohale® 200

    Product Lactohale® 200

    Lactohale® 200 is milled lactose produced with a tightly controlled mean particle size. The size of the particles of Lactohale® 200 can be controlled and but also varied by gentle milling. This means that different D50's can be produced depending on the degree of milling to match the customer's requirement. The fine content of Lactohale® 200 can also be controlled by removing the fines by air classifying, followed by blending fines with the coarse to meet a particular target profile.

  • Lactohale® 206

    Product Lactohale® 206

    Lactohale® 206 is a milled grade of alpha-monohydrate lactose where the fine lactose particles have been removed. The mean particle size can be tightly controlled by milling to match the customer’s requirement.

    Customers can further optimise their inhaled formulation for flow and deposition by blending with one of the fine grades of DFE Pharma (for example with Lactohale® 210, 220, 230, 300). Lactohale® 206 is therefore especially of interest for formulators who are in early stage of development process or others who want to explore the design space of their formulation.

  • Lactohale® 300

    Product Lactohale® 300

    Lactohale® 300 is a very fine and micronised lactose with a D50 below 5 microns. Lactohale® 300 is applied to Dry Powder Inhalation formulation to improve the drug deposition or optimize the flow properties of their formulation. In addition, Lactohale® 300 can be blended with several coarse lactose grades to develop customer specific lactose blends and with active pharmaceutical ingredients for agglomerates of drug and microfine lactose particles.

  • Respitose® SV014

    Product Respitose® SV014

    Respitose® SV014 is a sieved inhalation-grade lactose grade with excellent flow properties and very large lactose crystals. It’s optimal flow properties provides opportunities for application in reservoir devices or to maintain the required flow and content uniformity in high dose inhalation formulations. This product can also be utilized as a “sweepener”, where the lactose deagglomerates the drug particles in an inhalation device during inhalation, propelling the drug into the respiratory tract. Respitose® SV014 is produced in a dedicated facility in Veghel, the Netherlands.

DFE Pharma Resources

  • News Excipients – an industry adapting to change

    Excipients are a crucial component of the pharmaceutical product formulation, and the industry is constantly having to adapt to changes in demand and technology innovations
  • Video DFE Pharma Norten Hardenberg, Germany

    DFE Pharma's Norten Hardenberg plant, located in Germany, is dedicated to the production of anhydrous lactose. An investment for the future, featuring a new state-of-the-art production line, like for like process, high-end control to ensure batch homogeneity.
  • Whitepaper Understanding and Accounting for Excipient Variability in Continuous Tablet Manufacturing (CM)

    As pharmaceutical production moves from batch-wise to continuous manufacturing, individual processing steps, such as blending of the active pharmaceutical ingredient (API) with excipients, have to be re-designed to continuous operations.

    Whilst the cost and quality benefits of CM are well documented, successful implementation relies on an in-depth understanding of how raw materials and their mixtures – including excipients – behave in continuous processes. This whitepaper will outline some of the key learnings from DFE Pharma’s excipients in CM processes variability experiments, before setting out DFE Pharma’s Stretch Batch Approach and how it can work in practice.
    Ultimately, it will demonstrate why DFE Pharma is fast becoming the pharma industry’s preferred global partner in the robust development of continuous tablet manufacturing processes.
  • Video Biohale® Trehalose Dihydrate Launch

    With BioHale® Trehalose, the latest addition to the BioHale® portfolio line, DFE Pharma expands its offering of stabilizers for biologics while providing further security of supply. Trehalose – developed to meet the highest quality standards - can be used in parenteral formulations, but is also part of inhalation pipeline projects. #biopharma #biologics #formulation
  • Video We Are DFE Pharma

    DFE Pharma is a global leader in excipient products and services for usage in the pharmaceutical, biopharmaceutical, and nutraceutical industries. We strive to develop, produce and supply the highest quality functional excipients for oral solid dose, inhalation, and parenteral formulations. Our products play essential roles as fillers, binders, disintegrants, and stabilizing agents in formulations. 

    They enable the active ingredients to be dosed and released into the patients' system in a predictable, accurate, and effective manner. With over a century of experience, we are driven by our purpose your medicines, our solutions. Moving to a healthier world. #pharma #DFEPharma #excipients